Institute for Quality and Efficiency in Health Care

Added benefit of idelalisib is not proven

Idelalisib (trade name Zydelig) has been available since September 2014 for patients with follicular lymphoma or chronic lymphocytic leukaemia (CLL). The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Jan 08, 2015
popularity not rated yet | comments 0

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Dec 10, 2014
popularity not rated yet | comments 0

Added benefit of vedolizumab is not proven

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Oct 23, 2014
popularity not rated yet | comments 0